Literature DB >> 10998531

Nociceptin and neurotransmitter release in the periphery.

S Giuliani1, A Lecci, C A Maggi.   

Abstract

Nociceptin exerts a general modulatory effect on transmitter release from sympathetic, parasympathetic, NANC and sensory nerve endings in the peripheral nervous system in various species. This effect occurs at a prejunctional level and is independent from the activation of mu, delta and kappa opioid receptors. Despite the growing evidence describing the peripheral activity of nociceptin since its discovery in 1995, the lack of selective and potent antagonists does not allow us to draw conclusions on the putative physiological role of this peptide at this level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998531     DOI: 10.1016/s0196-9781(00)00237-0

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Nociceptin inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse.

Authors:  S L Borgland; M Connor; M J Christie
Journal:  J Physiol       Date:  2001-10-01       Impact factor: 5.182

3.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

4.  Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

Authors:  Robbie L McLeod; Deen B Tulshian; Donald C Bolser; Geoffrey B Varty; Marco Baptista; Xiomara Fernandez; Leonard E Parra; Jennifer C Zimmer; Christine H Erickson; Ginny D Ho; Yanlin Jia; Fay W Ng; Walter Korfmacher; Xiaoying Xu; John Veals; April Smith-Torhan; Samuel Wainhaus; Ahmad B Fawzi; Theodore M Austin; Margaret van Heek; John A Hey
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

5.  Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.

Authors:  Kinga Sałat; Anna Furgała; Robert Sałat
Journal:  Inflammopharmacology       Date:  2017-10-25       Impact factor: 4.473

Review 6.  New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Authors:  Irene Simonetta; Renata Riolo; Federica Todaro; Antonino Tuttolomondo
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.